Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Southern Cross Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (263)
Cancellation by sponsor (201)
Prescription medicine registration (22)
Australian Public Assessment Report (AusPAR) (4)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2024 (16)
2023 (30)
2022 (102)
2021 (32)
2020 (52)
2019 (59)
2018 (35)
2017 (51)
2016 (22)
2015 (17)
2014 (9)
2013 (11)
2012 (19)
2011 (9)
2010 (10)
2009 (13)
2008 (3)
2007 (1)
2003 (1)

Results for "[search-keyword]"

Search

Sponsor content

492 result(s) found, displaying 11 to 20

FENOFIBRATE AJS fenofibrate 145 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
PREGABALIN APOTEX pregabalin 300 mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
PREGABALIN APOTEX pregabalin 150 mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
PREGABALIN APOTEX pregabalin 75 mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
PREGABALIN APOTEX pregabalin 25 mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
OMEPRAZOLE GENERICHEALTH omeprazole 20 mg enteric-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
PHARMACY ACTION PHARMISIL terbinafine hydrochloride 10 mg/g cream tube (407304)

4 April 2023

ARTG

Australian Register of Therapeutic Goods (ARTG) information for PHARMACY ACTION PHARMISIL terbinafine hydrochloride 10 mg/g cream tube.
DAPTOMYCIN GH daptomycin 350 mg powder for injection vial (383873)

27 February 2023

ARTG

Australian Register of Therapeutic Goods (ARTG) information for DAPTOMYCIN GH daptomycin 350 mg powder for injection vial.
DAPTOMYCIN LUPIN daptomycin 500 mg powder for injection vial (383872)

27 February 2023

ARTG

Australian Register of Therapeutic Goods (ARTG) information for DAPTOMYCIN LUPIN daptomycin 500 mg powder for injection vial.
DAPTOMYCIN LUPIN daptomycin 350 mg powder for injection vial (383871)

27 February 2023

ARTG

Australian Register of Therapeutic Goods (ARTG) information for DAPTOMYCIN LUPIN daptomycin 350 mg powder for injection vial.

Pages

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.